

CELL- PERMEABLE SUCCINATE RESCUES PLATELET MITOCHONDRIAL RESPIRATION IN COVID-19 PATIENTS

Paul Bîcă¹, Radu N. Burghelea², Anca M. Bîcă^{3,4}, Anca Paraschivoiu⁵, Ovidiu Bedreag⁶, Dorel Săndesc⁶, Claudia Borza^{3,4}, Adrian Neagu⁷, Octavian M. Crețu⁸, Danina M. Muntean^{3,4}

¹Doctoral School Medicine-Pharmacy, "Victor Babeș" University of Medicine and Pharmacy Timișoara; Clinic of Anaesthesia and Intensive Care, "Pius Brînzeu" Emergency County Hospital, Timișoara, Romania

²Emergency City Hospital, Clinic of Anaesthesia and Intensive Care, Timișoara, Romania

³Department III - Pathophysiology, "Victor Babeș" University of Medicine and Pharmacy Timișoara, Romania

⁴Centre for Translational Research and Systems Medicine, "Victor Babeș" University of Medicine and Pharmacy Timișoara, Romania

⁵Dr. Victor Popescu" Military Emergency Hospital, Timișoara, Romania

⁶Department X - Anaesthesia and Intensive Care, "Victor Babeș" University of Medicine and Pharmacy Timișoara; Clinic of Anaesthesia and Intensive Care, "Pius Brînzeu" Emergency County Hospital Timișoara, Romania

⁷Department III - Biophysics, "Victor Babeș" University of Medicine and Pharmacy Timișoara, Romania

⁸Department IX - Surgical Semiotics 1, "Victor Babeș" University of Medicine and Pharmacy Timișoara, Romania

The COVID-19 pandemic remains a global health issue since its outbreak. Hyperinflammation with "cytokine storm", endothelial dysfunction, and more recently, mitochondrial dysfunction were identified as main pathomechanisms. Platelet respiratory dysfunction has recently emerged as a peripheral biomarker that could mirror organ mitochondrial dysfunction. NV118, a cell-permeable succinate, is a new prodrug able to support mitochondrial function by enhancing complex II-supported respiration.

The present pilot study performed in platelets harvested from patients hospitalized for various forms of SARS-CoV2 infection was double-aimed: i) to assess the mitochondrial respiratory dysfunction; ii) to investigate whether NV118 can rescue it.

Nineteen patients with moderate (n=5) and severe (n=14) disease were included. Peripheral blood was collected and used for platelet isolation. Platelet respiration was measured at 37°C using high-resolution respirometry according to a SUI protocol for permeabilized platelets allowing the measurement of the following respiratory parameters: routine, active, non-phosphorylating and maximal uncoupled respiration. Intact platelets (n=15) were acutely exposed to NV118 (vs DMSO) and routine, leak and maximal uncoupled respiration were measured.

The severe forms of disease expressed a significant decrease in platelet active respiration for both respiratory complexes and an increase of routine, leak and uncoupled respiration. Moderate forms of disease present only a significant decrease in active respiration, particularly for CI. Cell-permeable succinate elicited a significant increase in routine, leak and maximal uncoupled respiration for both mitochondrial complexes.

In conclusion, COVID-19 differentially impairs platelet bioenergetics, according to the severity of the disease, eliciting mitochondrial respiratory dysfunction that can be rescued by cell-permeable succinate.

Keywords: COVID-19, platelets, mitochondria, high-resolution respirometry, cell-permeable succinate